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Statement of clinical 
relevance
In osteoporosis-pseudoglioma syndrome 
(OPPG), skeletal fragility predisposes to 
frequent fracturing with consequent physical 
handicap, while the ocular complications 
result in defective vision or blindness. OPPG 
has serious clinical consequences and since 
several South African (SA) Indians have a 
common geographical origin, it is possible that 
the determinant gene exists with significant 
frequency in this population. For this reason, 
the authors hope to bring this extremely rare 
disorder to the attention of the SA medical 
community.
Background
OPPG (MIM 259770) is a rare autosomal 
recessive condition that is characterised by 
severe osteoporosis and eye abnormalities 
leading to loss of vision. Affected persons 
present with multiple fractures, and the 
skeletal manifestations closely resemble 
those of osteogenesis imperfecta (OI), while 
hyperplasia of the vitreous, and eye and 
corneal opacities can mimic an intraocular 
glioma. These manifestations are progressive, 
and affected individuals may have considerable 
physical handicap and visual disturbance.
In 1985, an SA Indian family, in which 
4 brothers and 2 sisters had severe osteo-
porosis and blindness, were reported on in 
an article: ‘The ocular form of osteogenesis 
imperfecta’. [1] It was subsequently suggested 
that this was actually OPPG and this diagnosis 
was acknowledged by the authors.[2]
Methods
All investigations were undertaken with 
full ethical approval in accordance with the 
Declaration of Helsinki as updated in the 
version promulgated in June 2013, and the 
Singapore Statement on Research Integrity.
During the clinical investigations of 
indi viduals with thin bone disorders as a 
component of a PhD thesis registered in the 
Division of Human Genetics at the University 
of Cape Town, two persons with a confirmed 
diagnosis of OPPG were identified. They were 
the nephew (SB) and his uncle (BB), who 
were the only surviving affected members of 
the family described in 1985.[1] In addition, 
two SA females (HB and BA) of Indian 
descent were identified with osteoporosis and 
ocular problems of unknown origin. All four 
individuals had a common ancestral origin 
from the state of Gujarat in India. 
Family background of SB and BB
The progenitors of the affected persons 
arrived in SA circa 1890 from Gujarat, 
in the north-western region of the 
Indian subcontinent. The kindred were 
consanguineous and several relatives in 
India were said to have had the condition. 
(Fig. 1) 
The condition remains rare in SA and no 
other affected families have been identified 
in any of the populations of this country or 
in any other region of sub-Saharan Africa.
Affected person I (SB)
The affected nephew was born in Durban, 
SA in 1967. He was blind at birth and in 
infancy, and hyperplasia of the vitreous was 
diagnosed by an ophthalmologist. At age 5 
years he was admitted to the New Horizon 
School for the Blind in Pietermaritzburg. 
His performance at this institution was good 
and he is currently satisfactorily employed 
as a radio disc jockey. He was diagnosed 
with osteogenesis imperfecta at the age 
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Fig. 1. The pedigree of the affected family.
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of 10 years on the basis of radiographic 
investigations. He recollected having sus-
tained approximately four fractures of 
his lower limbs, which resulted in limb 
deformity (Fig. 2).
Affected person II (BB)
The affected uncle (BB) was born in 1949 
in Durban. He recollected that as a young 
boy, he was blind in his left eye and only 
had partial sight in his right eye. At 15 years 
of age, he became completely blind, and 
when examined at the age of 63 years he 
had opacities of the globes of both eyes 
(Fig. 3). Available clinical reports stated that 
he had seven fractures of his long bones 
during childhood that resulted in marked 
limb deformities (Fig. 4). He became chair 
bound at the age of 25 years.
Affected person III (HB)
HB was the only affected person in 
her family. She had unaffected parents 
and three unaffected male siblings. At 
19 years of age, she had sustained more 
than 10 frac tures, was 112 cm in height, 
walked with an aid and was mildly visually 
impaired (Fig. 5). The nature of her visual 
disability was unknown and has not yet 
been investigated.
Affected person IV (BA)
BA was 15 years of age, 110 cm in height and 
walked with an aid (Fig. 6). Despite receiving 
bisphosphonate therapy, her parents gave 
a history of BA sustaining more than 50 
fractures. Her parents were unaffected and 
she had a younger unaffected male sibling. 
BA had mild visual impairment of unknown 
aetiology.
Discussion
HB and BA, were born in SA and, although 
a definite history of consanguinity could not 
be established, it may be relevant that the 
progenitors of both individuals hailed from 
Gujarat province in India. Individuals HB 
and BA were not investigated for OPPG, 
but the possibility that these individuals 
actually have OPPG cannot be discounted. 
An attempt by the author to contact their 
ophthalmologists was unsuccessful. An 
ophthalmic opinion and further molecular 
investigations are warranted. The progeni-
tors of all four persons hailed from Gujarat 
in the north-western region of India. The 
issue of consanguinity could not be ruled 
out in the families of HB and BA, but was 
confirmed in the family of SB and BB.
The association of the clinical features 
of ocular involvement and bone fragility 
were initially described in 1931.[3] 
Other early reports from 1967 to 1986 
concentrated predominantly on the 
clinical presentation of the syndrome.[2,4-
6] In 1955, Meyer described an atypical 
form of osteogenesis imperfecta using the 
designation ‘Lobstein’s disease’ and it has 
since been suggested that this condition 
might have been OPPG.[7] There have been 
Fig. 2. SB at the age of 45 years is blind and 
deformities of his legs are apparent.
Fig. 3. BB completely blind at age 63.
Fig. 4. BB had anterior bowing of his lower legs 
due to fractures sustained in childhood.
Fig. 5. HB aged 19 years.
Fig. 6. BA aged 15 years.
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other instances of reported phenotypic confusion between OI and 
OPPG.[1,2,8] The disorder has been described in association with 
mild mental retardation[6] and with congenital heart disease. [8] 
Other inconsistent manifestations of OPPG have included 
Wormian bones, frontal bossing and hyperextensible joints.[9] Blue 
sclerae, as in OI, is not a typical feature of OPPG, although this 
abnormality has been reported in two affected persons.[8]
The condition has a wide geographical distribution and it is present 
in several disparate countries. Following a review of 21 affected 
persons in eight families, it was suggested that there was a significant 
gene frequency in Mediterranean countries.[10] In a study conducted 
in the USA, the clinical and molecular findings were described in 
37 probands, and a population incidence of one in two million was 
estimated.[11] In 2008, a further nine new cases were reported at the 
Amish Research Clinic in Strasburg.[12] To date, affected individuals 
have been documented in France,[4,10] SA,[1] Greece,[10,13] India,[14] the 
USA[11,12] and Tunisia.[15]
Gong et al.[16] reported that the OPPG gene was located at 
chromosome region 11q12-13 on a basis of analysis of 16 DNA 
samples, including specimens from the SA family. Thereafter, 
Gong et al.[17] showed that mutations in the low-density lipoprotein 
receptor-related protein 5 gene (LRP5) caused OPPG in the SA 
nephew (SB) and his uncle (BB) and other affected families. 
Using biological material from the studies of Gong et al.,[17] the 
specific mutation in the SA family was identified as 3804delA. [11] 
The LRP5 gene affects bone mass accrual during growth, and 
heterozygous carriers of the mutant gene have reduced bone mass 
when compared with matched controls.[17] These individuals fail 
to reach an adequate peak bone mass.[12] These findings have been 
further confirmed by the demonstration that inactivation of LRP5 
in osteocytes results in impaired bone size and mass in response to 
mechanical loading.[18]
Although in the majority of cases of OPPG there is loss of 
function of the LRP5 gene, no mutation has been detected 
in a significant number of cases. Concepts have evolved and 
OPPG is now regarded as a member of an overlapping disorder, 
spondylo-ocular syndrome (SOS), which is also associated with 
eye abnormalities and vertebral compression fractures. Currently, 
there is no review specifically addressing the patterns of visual 
impairment in OPPG and SOS.[19]
The general management of OPPG by administration of 
bisphosphonates and the success thereof have been documented. [20] 
It has been recommended that patients with OPPG should begin 
treatment with bisphosphonates in the early years of life.[20] More 
recently, Arantes et al.[7] provided therapeutic insight into the 
management of OPPG and supported the rationale for using an 
osteoanabolic agent. Zhao et al.[18] suggested that increasing LRP5-
induced signalling in osteoblasts of persons with OPPG may be 
beneficial to the treatment of osteopaenia and osteoporosis.
Conclusion
The pedigree of SB and BB showed that six affected members of the 
family had brittle bones with associated blindness, and these data 
are consistent with autosomal recessive inheritance. At the time of 
their diagnosis, genetic counselling, as well as dedicated medical and 
social care, were the only forms of help that could be offered to these 
patients and their families. In the SA Indian community, marriages 
are often consanguineous and it can be postulated that there is a risk 
that further affected persons could be born in the extended family.
Since the four affected persons depicted in this article had a 
common ancestry from Gujarat, it seems possible that the determinant 
gene may be present in significant frequency in SA.
OPPG is similar to OI and SOS in terms of its pathology, and has 
serious clinical consequences. The improved molecular knowledge of 
this syndrome over the past decade has facilitated genetic counselling 
as well as provided successful genetic management options.
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